Los Angeles LGBT Center Announces Participation in STOMP, a Phase 3 Trial Evaluating Human Monkeypox Treatment - Los Angeles LGBT Center

Los Angeles LGBT Center Announces Participation in STOMP, a Phase 3 Trial Evaluating Human Monkeypox Treatment

October 12, 2022
Contact: Media Relations

The Los Angeles LGBT Center, the largest LGBT non-profit in the world, is pleased to announce its participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat (commonly known as TPOXX) for the treatment of human monkeypox. STOMP, which is being led by the AIDS Clinical Trials Group (ACTG), has been designed to learn as much as possible in a broad population of people with human monkeypox. For information about enrolling in the trial at the Los Angeles LGBT Center or to learn more about the study, please email [email protected] or visit https://www.stomptpoxx.org/stompsites

“There is an urgent need for FDA-approved human monkeypox treatments, and this study will help us determine whether tecovirimat should be one of them,” said Robert Bolan, MD, Medical Director of Research and Education at the Los Angeles LGBT Center. “I believe STOMP is a well-designed trial which provides careful follow-up so that participants can be assured of the most appropriate treatment for their infection. People living in the Los Angeles area who have monkeypox infection can make a huge contribution by participating in this study.”

A global outbreak of monkeypox emerged in the spring of 2022 and has since spread throughout the world, with more than 56,000 cases in 103 countries and more than 21,000 cases in the United States. Human monkeypox was first identified in 1958 and has caused an increasing number of infections annually in endemic countries. The current outbreak has been characterized by increased person-to-person transmission. Close contact during sexual activity is believed to play an important role in this outbreak. While most cases thus far have been reported among men who have sex with men, women and children have also been infected. There are currently no therapies approved to treat human monkeypox.

Tecovirimat (SIGA Technologies, Inc.) is approved by the U.S. Food and Drug Administration (FDA) to treat smallpox, but it is not yet known if it can effectively or safely treat human monkeypox.

This multi-center trial will enroll more than 500 adults with human monkeypox virus infection. Importantly, this trial will include people with severe disease and those at high risk of severe disease, including pregnant and breastfeeding people, children, and individuals with underlying immune deficiency and active inflammatory skin conditions who will receive open-label tecovirimat. Study participants with symptomatic monkeypox virus infection who do not meet the criteria for the open-label cohort will be randomly assigned in a ratio of 2-to-1 to receive either tecovirimat or placebo orally for 14 days. Participants who are randomized in the double-blinded cohort of the study who later progress to severe disease will be offered the option to switch to open-label tecovirimat, as will participants who report persistent severe pain from monkeypox virus infection.

All participants in STOMP will be followed for at least eight weeks through a combination of virtual and in-person visits, and daily self-reports to determine if those receiving tecovirimat heal more quickly compared to those receiving placebo. STOMP will also provide critical data on the optimal dosing and safety of tecovirimat in children and people who are pregnant and breastfeeding.

Individuals who have presumptive or confirmed human monkeypox infection (testing positive within seven days) and started experiencing symptoms within 13 days are eligible. Testing will be provided by the study. Participants with presumptive monkeypox virus infection who have not yet been tested are able to enroll as long as their study-provided test is positive. Participants must also have at least one active skin lesion that has not yet scabbed, a mouth lesion, or proctitis (inflammation in the lining of the rectum).

“The ACTG has designed this study to give us the greatest possible insights into whether and how tecovirimat works against monkeypox, including whether the virus develops resistance to the treatment,” said ACTG chair Judith Currier, M.D., M.Sc., University of California, Los Angeles. “An important part of that design is the inclusion of children and pregnant people. The study will also evaluate markers that may tell us that the drug is working so we can identify future promising drugs. Beyond addressing the current outbreak, this study has the potential to profoundly inform the treatment of individuals who acquire monkeypox virus in endemic countries.”

STOMP is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), which also funds the ACTG.  A list of participating sites in the United States can be found here: https://www.stomptpoxx.org/stompsites

STOMP is led by Timothy Wilkin, M.D., M.P.H., Weill Cornell Medicine and William Fischer, M.D., University of North Carolina (UNC) and Jason Zucker, M.D., Columbia University (vice-chairs) and is supported by Dr. Currier and Joseph J. Eron, M.D., UNC (ACTG Co-Chair).

For more information about STOMP, please visit the ACTG website

About the Los Angeles LGBT Center

Since 1969 the Los Angeles LGBT Center has cared for, championed, and celebrated LGBT individuals and families in Los Angeles and beyond. Today the Center's nearly 800 employees provide services for more LGBT people than any other organization in the world, offering programs, services, and global advocacy that span four broad categories: Health, Social Services and Housing, Culture and Education, Leadership and Advocacy. We are an unstoppable force in the fight against bigotry and the struggle to build a better world; a world in which LGBT people thrive as healthy, equal, and complete members of society. Learn more at lalgbtcenter.org.

Giving Tuesday $50,000 Match by US Bank

If you think you or your family member has a medical or psychiatric emergency, call 911 or go to the nearest hospital. Do not attempt to access emergency medical care through this contact email.

If you are an established client of the Center with a non-emergency medical question, please call 323-993-7500.

Examples of the kinds of questions that you can send to this email are:

  • What are your hours?
  • Do I have to have insurance to come there?
  • Can I get my name changed there?

By clicking continue I understand that I should use this mail box only for a non-emergency, non-urgent question.

One or more fields is empty.Invalid Email Address